Intermediate dose recombinant interferon-α as second-line treatment for patients with recurrent cutaneous melanoma who were pretreaterd with low dose interferon

Cancer

Volumn 89, Issue 7, 2000, Pages 1490-1494

  Ascierto, Paolo A ^a,c   Daponte, Antonio ^a   Parasole, Rosanna ^a   Perrone, Francesco ^a   Carac, Corrado ^a   Melucci, Mariateresa ^a   Palmieri, Giuseppe ^b   Napolitano, Maria ^a   Mozzillo, Nicola ^a   Castello, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Institute of Molecular Genetics   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant treatment; Interferon; Melanoma; Second line

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DOSE RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; INSOMNIA; LEUKOPENIA; MALE; MELANOMA; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TUMOR; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0034307244     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001001)89:7<1490::AID-CNCR11>3.0.CO;2-V     Document Type: Article

References (22)

1. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells
2. Effects of interferons and cytokines on melanoma cells
3. Randomized, surgical adjuvant clinical trial of recombinant interferon alpha-2a in selected patients with malignant melanoma
4. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
5. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high- and low-dose IFNα2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma
6. Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastasis
7. Results of adjuvant interferon study in WHO melanoma programme
8. The WHO low dose adjuvant interferon study: An update
9. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases; French Cooperative Group on Melanoma
10. Adjuvant interferon alpha-2a treatment in resected primary Stage II cutaneous melanoma
11. Adjuvant therapy of cutaneous melanoma
12. Three-year treatment with recombinant intefferon-a as adjuvant therapy of cutaneous malignant melanoma
13. Reporting results of cancer treatment
14. Role of interferons in the therapy of melanoma
15. Malignant melanoma: Biotherapeutic strategies for management with interferons
16. Immunological and clinical effects of intramuscular rIFNα-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma
17. Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma
18. Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma
19. Chromosomal evolution in the progression and metastasis of human malignant melanoma
20. Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors
21. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression
22. Homozygous loss of the p15(INK4B) gene (and not the p16(INK4) gene) during tumor progression in a sporadic melanoma patient